Shubham Singh

Dexcom unveiled the G8, a self-adapting CGM platform it calls a complete step change, while setting a 10% annual revenue growth floor through 2030. A Medicare coverage decision expected before year-end could also double its US addressable market.

The Dutch insulin pump maker is launching its Kaleido system with Diabeloop's DBLG2 algorithm and Dexcom G7 in Germany and the Netherlands this summer – and has its sights set on the US by 2027.

India's medical device sector has hit a genuine turning point – domestic manufacturing share has doubled, capital is flooding in, and a clutch of homegrown innovations are reaching global markets. A new report sets out exactly what is at stake and what could still go wrong.

The system, built on the existing ClarityIQ platform, uses over 50% less X-ray radiation than the lowest-dose settings previously available on Azurion – with a blinded clinical study suggesting improved image quality in the majority of comparisons.

The deal adds a temporary peripheral nerve stimulation platform to Medtronic's neuromodulation lineup, positioning the company to intervene earlier in patients' chronic pain journeys.

A new study finds mid-market healthcare companies are among the most aggressive AI adopters, yet security concerns are blocking 67% of firms from scaling further.

A head-to-head crossover trial and real-world data from more than 20,000 patients point to the same conclusion: in automated insulin delivery, the algorithm matters more than the sensor. MiniMed's 780G system is now backed by mounting evidence – and a fresh Nasdaq listing.

The FDA's breast density rule reached 40 million women – but stopping at disclosure left a structural gap no technology has yet filled. QT Imaging's CEO explains why the real barriers are capacity, reimbursement and a screening system never built for what comes next.

Stryker's Pangea Plating System has reached Europe, two years after its US debut. With its first clinical case completed in London, the platform now enters a $7.8bn trauma fixation market – and into a direct fight with DePuy Synthes, Zimmer Biomet and entrenched surgeon loyalties.

New research exposes a series of strategic disconnects between what providers need and what manufacturers deliver, just as patient-initiated testing threatens to reshape the market.